Cargando…
Preadmission Oral Anticoagulation for Atrial Fibrillation/Flutter and Death or Thrombotic Events During COVID-19 Admission
Atrial fibrillation/flutter (AF) and COVID-19 are associated with an elevated risk of arterial and venous thrombosis. Whether preadmission oral anticoagulation (OAC) for AF reduces the incidence of in-hospital death or thrombotic events among patients with COVID-19 is unknown. We identified 630 pati...
Autores principales: | Louis, David W., Kennedy, Kevin F., Saad, Marwan, Salber, Greg, Imran, Hafiz, Wark, Tyler, Soares, Cullen, Ghosalkar, Dhairyasheel, Cherala, Rasan, Poppas, Athena, Abbott, J. Dawn, Aronow, Herbert D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374502/ https://www.ncbi.nlm.nih.gov/pubmed/35970632 http://dx.doi.org/10.1016/j.amjcard.2022.07.006 |
Ejemplares similares
-
PRE-ADMISSION ORAL ANTICOAGULATION IS ASSOCIATED WITH FEWER THROMBOTIC COMPLICATIONS IN PATIENTS ADMITTED WITH COVID-19
por: Louis, David, et al.
Publicado: (2022) -
Preadmission Statin Treatment and Outcome in Patients Hospitalized With COVID-19
por: Saad, Marwan, et al.
Publicado: (2022) -
Effect of preadmission beta‐blockade on mortality in multiple trauma
por: Eriksson, M., et al.
Publicado: (2018) -
Eosinophilic Myocarditis in a Patient With Sickle Cell Disease
por: Imran, Hafiz M., et al.
Publicado: (2021) -
Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
por: Fradley, Michael G., et al.
Publicado: (2020)